Market Research Reports Alzheimer's Disease Patient Digital Landscape | Page 2

Alzheimer. Despite the fact that Alzheimer's disease is not treatable, symptomatic treatment is
followed in all cases. Research is being completed to create treatment fixated on the job of beta-
amyloid in Alzheimer's disease.
The Global Alzheimer’s Disease Market is segmented on the basis of Drugs Class, Distribution
Channels and Region. Based on the Drugs Class, the Global Alzheimer’s Disease Market is sub-
segmented into Cholinergic, Memantine, Combined Drug and others. On the basis of Distribution
Channels, the Global Alzheimer’s Disease Market is classified into Hospital Pharmacy, Retail
Pharmacy, and Online Sales.
Top Leading Key Players in Global Alzheimer’s Disease Market: Johnson & Johnson, Pfizer, Janssen
Pharmaceutical, Novartis International AG, Eisai Co. Ltd., Lundbeck A/S, Teva Pharmaceuticals
Industries Ltd. and others. New product launches and continuous technological innovations are the
key strategies adopted by the major players.
Latest Industry News:
1 Teva Pharmaceuticals Industries (May 28, 2019) – Teva Announces Launch of a Generic Version of
Ranexa (ranolazine) Extended-Release Tablets in the United States – Teva Pharmaceutical Industries
Ltd., today announced the launch of a generic version of Ranexa (ranolazine) Extended-Release
Tablets, 500 mg and 1000 mg, in the U.S.
Ranolazine Extended-Release Tablets are indicated for the treatment of chronic angina.
“We’re pleased to add to our portfolio of generic medicines that offer another treatment option for
people living with chronic conditions like angina,” said Brendan O’Grady, EVP and Head of North
America Commercial.
With nearly 500 generic medicines available, Teva has the largest portfolio of FDA-approved generic
products on the market and holds the leading position in first-to-file opportunities, with over 100
pending first-to-files in the U.S. Currently, one in eight generic prescriptions dispensed in the U.S. is
filled with a Teva generic product.
2 Pfizer (May 24, 2019) – Pfizer Announces Top-line Results From Phase 3 Trial of Lyrica (Pregabalin)
in Primary Generalized Tonic-clonic Seizures – Pfizer Inc. (NYSE: PFE) announced today that a Phase 3
study to assess the use of LYRICA (pregabalin) as adjunctive therapy for epilepsy patients 5 to 65
years of age with primary generalized tonic-clonic (PGTC) seizures did not meet its primary endpoint.
Treatment with LYRICA did not result in a statistically significant reduction in seizure frequency
versus placebo. Lyrica is not indicated in any population for the treatment of PGTC seizures. The
study was a post-marketing commitment to the U.S. Food and Drug Administration (FDA).
“Pfizer is committed to the study of patient populations with unmet treatment needs, including
pediatric and adult patients experiencing generalized tonic-clonic seizures,” said Juan Ovalle, M.D.,
Global Chief Medical Officer, R&D and Medical, Upjohn, a division of Pfizer. “These data contribute
to our growing understanding of pediatric epilepsy and reflect our responsibility to advance scientific
knowledge through post-marketing research.”